Query: stroke

Filtered By:
Drug: Pantoprazole

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction 
CONCLUSION: In patients with acute MI treated with PCI, lower dose-adjusted clopidogrel and dose-adjusted 2-oxo-clopidogrel plasma concentrations were associated with an increased risk of ischemic events.
. PMID: 30431425 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - November 17, 2018 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Acute aortic occlusion in a patient without risk factors
A 94-year-old female with a history of ischemic stroke, mild right hemiparesis, vascular dementia, breast cancer with right mastectomy, colon cancer resulting in colectomy, hyperlipidemia, and hypertension presented to the emergency department (ED) with bilateral leg pain. Patient had no smoking history, and her medications included Donepezil, Aspirin, Citalopram, Losartan, and Pantoprazole.
Source: The American Journal of Emergency Medicine - March 28, 2018 Category: Emergency Medicine Authors: Trina Stoneham, Erin L. Simon Source Type: research

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular OutcoMes for People Using Anticoagulation StrategieS (COMPASS) Trial
Conclusion COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy. Teaser COMPASS is a global randomized controlled trial comparing rivaroxaban 2.5mg twice-daily plus aspirin 100mg once-daily, rivaroxaban 5mg twice-daily, and aspirin 100mg once-daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable coronary or peripheral artery ...
Source: Canadian Journal of Cardiology - June 8, 2017 Category: Cardiology Source Type: research

Hemopericardium under dabigatran for stroke prevention in atrial fibrillation
We report a polymorbid 75-year old male under a therapy with dabigatran, valsartan, amlodipine, nicorandil, furosemide, atorvastatin, bisoprolol, metformin, tizanidine, pantoprazole, and tramadol. He suffered from chest pain for 4 months. Coronary angiography showed only ectatic coronary arteries. He started taking nonsteroidal anti-inflammatory drugs. He was hospitalized because of dyspnea starting 10 days before admission, melena, and renal failure. Hemopericardium was diagnosed and pericardiocentesis yielded 2000 ml hemorrhagic fluid. Review of previous echocardiograms showed a 4 mm echo-free space, epicardial fat o...
Source: Blood Coagulation and Fibrinolysis - February 11, 2017 Category: Hematology Tags: Case Reports Source Type: research

Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Abstract PURPOSE: We performed a systematic review of patient-centered outcomes after the concomitant use of proton pump inhibitors (PPIs) and other drugs. METHODS: We searched 4 databases in July 2016 to find studies that reported mortality and morbidity after the concomitant use of PPIs and other drugs. We conducted direct meta-analyses using a random-effects model and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach. FINDINGS: We included data from 17 systematic reviews and meta-analyses, 16 randomized controlled t...
Source: Clinical Therapeutics - February 8, 2017 Category: Drugs & Pharmacology Authors: Shamliyan TA, Middleton M, Borst C Tags: Clin Ther Source Type: research

This Popular Kind Of Heartburn Medicine Can Increase Stroke Risk
This study further questions the cardiovascular safety of these drugs,” Sehested said. Although the study found an association between PPIs and stroke risk, it does not prove cause and effect. More studies are needed, and doctors should consider if and for how long patients should take these drugs, the researchers said. [7 Bizarre Drug Side Effects] PPIs are not the only medicines available to treat heartburn. The researchers noted that another type of heartburn medication, called a histamine H2 antagonist, was found to have no association with stroke risk in the study. Histamine H2 antagonists include famotidine (Pe...
Source: Science - The Huffington Post - November 21, 2016 Category: Science Source Type: news

Popular heartburn medications linked to higher risk of stroke
Proton pump inhibitors, including Prilosec, Protonix, Prevacid and Nexium, are used to treat heartburn, but may increase the risk of ischemic stroke, new research shows.
Source: CNN.com - Health - November 15, 2016 Category: Consumer Health News Source Type: news

Could Common Heartburn Drugs Up Stroke Risk?
TUESDAY, Nov. 15, 2016 -- A popular category of heartburn medications -- including Nexium, Prevacid, Prilosec and Protonix -- may increase your risk of stroke, a new study suggests. Known as proton pump inhibitors (PPIs), these drugs increased...
Source: Drugs.com - Daily MedNews - November 15, 2016 Category: Journals (General) Source Type: news

A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran
ConclusionThe majority of patients enrolled either did not experience GIS at all, or their GIS resolved using either one individually, or a combination of the two strategies described.Trial registrationhttp://www.ClinicalTrials.gov identifier: NCT01493557.
Source: Cardiology and Therapy - October 4, 2016 Category: Cardiology Source Type: research

Link between indigestion drugs and dementia 'inconclusive'
Conclusion This study found people taking PPIs had a 44% higher risk of developing dementia in a seven-year period compared with those not taking the drugs. However, it's not accurate to say this was down to the PPIs – the study couldn't prove this, and there are many possible explanations. For a start, the groups weren't very similar. Those taking PPIs had poorer health, and were more likely to be taking a number of medicines and have conditions linked to a higher risk of dementia, such as diabetes and heart disease. After taking these factors into account in the analysis, the link between PPIs and dementia reduc...
Source: NHS News Feed - February 16, 2016 Category: Consumer Health News Tags: Medication Neurology Older people Source Type: news

Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review Coronary Heart Disease
Conclusions Several frequently used PPIs previously thought to be safe for concomitant use with clopidogrel were associated with greater risk of adverse cardiovascular events. Although the data are observational, they highlight the need for randomized controlled trials to evaluate the safety of concomitant PPI and clopidogrel use in patients with coronary artery disease.
Source: JAHA:Journal of the American Heart Association - October 29, 2015 Category: Cardiology Authors: Sherwood, M. W., Melloni, C., Jones, W. S., Washam, J. B., Hasselblad, V., Dolor, R. J. Tags: Coronary Heart Disease Source Type: research

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS Trial
Conclusions Among ACS patients managed without revascularization, use of PPIs did not result in a differential antiplatelet response between prasugrel vs. clopidogrel but was associated with a lower incidence of MI with prasugrel. These hypothesis-generating findings suggest that factors besides platelet reactivity may underlie the differential risk of MI observed by treatment assignment with PPI use.
Source: American Heart Journal - June 11, 2015 Category: Cardiology Source Type: research

Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors Clinical Sciences
Conclusions— PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel.
Source: Stroke - February 23, 2015 Category: Neurology Authors: Leonard, C. E., Bilker, W. B., Brensinger, C. M., Flockhart, D. A., Freeman, C. P., Kasner, S. E., Kimmel, S. E., Hennessy, S. Tags: Platelet function inhibitors, Acute Cerebral Infarction, Acute Stroke Syndromes, Antiplatelets, Epidemiology Clinical Sciences Source Type: research

Negative hemodynamic effects of pantoprazole at high infusion rates in mice
ConclusionAt higher infusion rates pantoprazole is able to induce negative hemodynamic responses. Especially in the setting of heart failure these effects can lead to significant impairment of cardiac function. Therefore high infusion rates of pantoprazole should be avoided especially in heart failure patients.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - December 1, 2014 Category: Cardiology Authors: Bernhard Unsöld, Nils Teucher, Michael Didié, Samuel Sossalla, Claudius Jacobshagen, Tim Seidler, Wolfgang Schillinger, Gerd Hasenfuß Tags: Original Research Article Source Type: research